A5070728487- Lipoproteins and Cardiovascular Health
- Cardiac Valve Diseases and Treatments
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Genetic Associations and Epidemiology
- Cancer, Lipids, and Metabolism
- Liver Disease Diagnosis and Treatment
- Cardiovascular Disease and Adiposity
- Lipid metabolism and disorders
- Infective Endocarditis Diagnosis and Management
- Atherosclerosis and Cardiovascular Diseases
- Bioinformatics and Genomic Networks
- Cardiovascular Function and Risk Factors
- Adipokines, Inflammation, and Metabolic Diseases
- Cardiovascular Health and Risk Factors
- Cardiac Imaging and Diagnostics
- Cancer-related molecular mechanisms research
- Aortic Thrombus and Embolism
- Obesity, Physical Activity, Diet
- Antiplatelet Therapy and Cardiovascular Diseases
- Physical Activity and Health
- RNA modifications and cancer
- Diet, Metabolism, and Disease
- Health Systems, Economic Evaluations, Quality of Life
- Sphingolipid Metabolism and Signaling
- Prenatal Screening and Diagnostics
Université Laval
2016-2025
Institut Universitaire de Cardiologie et de Pneumologie de Québec
2016-2025
Brigham and Women's Hospital
2012-2024
University of California, San Francisco
2011-2024
Broad Institute
2024
Imperial College London
2024
Lung Institute
2024
The University of Texas Health Science Center at San Antonio
2024
Massachusetts Department of Public Health
2024
Massachusetts General Hospital
2024
This 2022 European Atherosclerosis Society lipoprotein(a) [Lp(a)] consensus statement updates evidence for the role of Lp(a) in atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, provides clinical guidance testing treating elevated levels, considers its inclusion global risk estimation. Epidemiologic genetic studies involving hundreds thousands individuals strongly support a causal continuous association between concentration outcomes different ethnicities; is factor...
We sought to examine the incidence and clinical predictors of new-onset type 2 diabetes mellitus (T2DM) within 3 large randomized trials with atorvastatin. Statin therapy might modestly increase risk T2DM. used a standard definition excluded patients prevalent at baseline. identified baseline T2DM compared event rates in without In TNT (Treating New Targets) trial, 351 3,798 80 mg atorvastatin 308 3,797 10 developed (9.24% vs. 8.11%, adjusted hazard ratio [HR]: 1.10, 95% confidence interval...
Although a previous study has suggested that genetic variant in the LPA region was associated with presence of aortic valve stenosis (AVS), no prospective role for lipoprotein(a) levels pathophysiology AVS. Our objective to determine whether and common is strongly are an increased risk developing AVS.Serum were measured 17 553 participants European Prospective Investigation into Cancer (EPIC)-Norfolk study. Among these participants, 118 developed AVS during mean follow-up 11.7 years. The...
Lipoprotein(a) [Lp(a)], a major carrier of oxidized phospholipids (OxPL), is associated with an increased incidence aortic stenosis (AS). However, it remains unclear whether elevated Lp(a) and OxPL drive disease progression are therefore targets for therapeutic intervention.This study investigated on apolipoprotein B-100 (OxPL-apoB) levels activity, progression, clinical events in AS patients, along the mechanisms underlying any associations.This combined 2 prospective cohorts measured...
Mendelian randomization studies have highlighted that lipoprotein(a) [Lp(a)] was associated with calcific aortic valve disease (CAVD). Lp(a) transports oxidized phospholipids a high content in lysophosphatidylcholine. Autotaxin (ATX) transforms lysophosphatidylcholine into lysophosphatidic acid. We hypothesized ATX-lysophosphatidic acid could promote inflammation/mineralization of the valve.We documented expression ATX control and mineralized valves. By using different approaches, we also...
Abstract Features of the gut microbiota have been associated with several chronic diseases and longevity in preclinical models as well observational studies. Whether these relations underlie causal effects humans remains to be established. We aimed determine whether influences cardiometabolic traits risk human using a comprehensive 2-Sample Mendelian randomization approach. included exposures 10 gut-associated metabolites pathways 57 microbial taxa abundance. outcomes nine (fasting glucose,...
High-density lipoprotein (HDL) cholesterol levels are inversely related to risk for coronary artery disease (CAD). Because HDL particles heterogeneous in size and composition, they may be differentially associated with other cardiovascular factors risk.To study the independent relationships of particle concentration future CAD.Nested case-control within EPIC (European Prospective Investigation into Cancer Nutrition)-Norfolk cohort; baseline survey between 1993 1997, follow-up until November...
<b>Background:</b> Screening for increased waist circumference and hypertriglyceridemia (the hypertriglyceridemic-waist phenotype) has been proposed as an inexpensive approach to identify patients with excess intra-abdominal adiposity associated metabolic abnormalities. We examined the relationship between phenotype risk of coronary artery disease in apparently healthy individuals. <b>Methods:</b> A total 21 787 participants aged 45–79 years were followed a mean 9.8 (standard deviation 1.7)...
Cardiovascular events occur among statin-treated patients, albeit at lower rates. Risk factors for this "residual risk" have not been studied comprehensively. We aimed to identify determinants of risk above and beyond lipid-related factors.A total 9251 coronary patients with low-density lipoprotein cholesterol <130 mg/dL randomized double-blind atorvastatin 10 or 80 mg/d in the Treating New Targets (TNT) study had complete on-treatment 1-year lipid data. Median follow-up was 4.9 years. The...